ACEM Pharmacology Flashcards
Mechanism of action of atropine
a competitive reversible muscuranic ACh receptor agonist
Anticholinergic activity
equally powerful at M1 M2 M3 receptors
minimal effect of nicotinic receptors
Pharmacokinetics of atropine
Administration: IV oral topical nebulized/inhaled
Distribution: wide Vd including into CNS
Metabolism and excretion: Half life is 2 hours, 60% is excreted unchanged via kidneys. 40% undergoes phase I and phase II metabolism and then renally excreted
Organ effects of atropine
Eye - mydriasis and cycloplegia
CNS delerium decreased tremor in parkinsons
CVS tachycardia
Resp bronchodilation and decreased secretions
GIT decreased saliva decreased gastric acid secretion decreased mucin production delayed gastric emptying decreased gut motility
Urinary relaxes ureteric and bladder wall smooth muscle urine retention
Skin decreased sweating
Clinical use of atropine
Treatment of symptomatic bradycardia or bradyarrhythmias
in opthalmology for mydriasis (dilate pupils)
occasionally used in RSI in paediatrics
drying of secretions in palliative patients
travellers diarrhoea
Atropine toxicity effects
Agitation, delirium
raised temperature
blurred vision, mydriasis
flushed skin
dry mouth
tachycardia
(mad as a hatter, blind as bat, red as a beet, dry as a bone)
What is the mechanism of action of indirectly acting cholinomimetics
(acetylcholinesterase inhibitors)
inhibit acetylcholinesterase enzyme
increasing concentration of Ach in the vicinity of cholinoreceptors
action on both nicotinic and musarinic receptors
what type of indirectly acting cholinomimetics (acetylcholinesterase inhibitors) are there ?
Reversible - neostigmine, physostigmine, pyridostigmine
Irreversible - organophosphates and insecticides
Cardiovascular effects of Indirectly acting cholinomimetics (acetylcholinesterase inhibitors)
Both sympathetic and parasympathetic ganglia can be activated
Parasympathetic effects generally predominate -
bradycardia, decreased CO, decreased contractility
OVerdose may cause tachycardia and hypotension
Pharmacokinetics of Adrenaline?
Administration; IV, IM, subcut, nebulised. Poor oral absorption
Distribution: Crosses the placenta, does not cross blood brain barrier. 50% protein bound. Onset within seconds, duration 2 mins
Metabolism: terminated by metabolism in sympathetic nerve terminals by COMT and MAO. Circulating adrenaline metabolised by COMT
Elimination: metabolites excreted in urine
Pharmacodynamics of adrenaline?
Equal effects on alpha and beta receptors
Alpha - vasoconstriction
Beta1 - positive inotropic and chronotropic effects
Beta2 - smooth muscle relaxation in airways and skeletal muscle
Effects of adrenaline on other organs?
Respiratory - bronchodilation
Eyes - pupil dilation, decreased IOP and production of aqueous humour
Gastric smooth muscle - relaxation
Genitourinary - bladder smooth muscle relaxation
Liver - enhanced glycolysis
Increased production of sweat at apocrine glands
What receptors does noradrenaline act on ?
Predominantly alpha 1 - vascular smooth muscle constriction
some alpha 2 beta 1 and beta 2
How does noradenaline increase blood pressure?
Increase in both systolic and diastolic blood pressure
Alpha 1 activity - vasoconstriciton, increased peripheral resistance = increased diastolic pressure
Beta 1 activity - increased myocardial contractility = increased systolic BP
What effect does noradrenaline have on heart rate ?
Minimal change
Beta 1 increases heart rate
however,
compensatory baroreceptor reflex causes decrease in HR
Mechanism of action metaraminol ?
Direct alpha 1 agonist - vascular smooth muscle constriction
Classes of local anaesthetics
Aminoamides - Lignocaine, Bupivocaine, prilocaine
Aminoesters - procaine, benzocaine, tetracaine
Mechanism of action of lignocaine
Sodium channel blocker
Class 1B antiarrhytmic
Local anaesthetic
Blocks voltage gated sodium channels without altering the resting membrane potential
Toxic effects of Lignocaine
CNS; perioral or tongue numbness, metallic taste > nystagmus, tinnitus, muscle twitching, nausea, vomiting > seizures, sedation
CVS; arrhythmias, hypotension, worsening CCF
GIT; vomiting anorexia nausea
Haem; methaemoglobinaemia (increase in MetHb, become blue), most often with prilocaine
Mechanism of action of nitrous
Modulates GABA-A recetpors
Increased dynorphin release
NMDA agonist
low solubilty in the blood so reaches arterial tension rapidly, rapid equilibrium in the brain, fast onset and fast recovery
Organ effects of nitrous
CNS; analgesia amnesia increased cerebral blood flow
Renal; decrease GFR increased renal vascular resistance
CVS; dose dependent mycardial depression
Resp; reduced response to CO2 and hypoxia
GI; nausea, vomiting
Pharmacokinetics of propofol
Administration; IV only
Distribution; rapid onset and recover is driven by redistribution of the drug from the brain to other areas. Half life 2-4 minutes, elimination half life up to 25 mins
Metabolism; rapidly metabolised in the liver
Elimination; Excreted in the urine as inactive metabolites
Usual induction dose of propofol
1-2.5mg/kg in adults
2.5-3.5mg/kg in paediatrics
Clinical effects of propofol
Anaesthesia/sedation
no analgesia
Transient apnoea
Decreased BP
anti-emetic properties
Adverse effects of Propofol
Hypotension
Apnoea
pain on injection
allergy/anaphylaxis
propofol infusion syndrome (a metabolic acidosis)
Pharmacodynamics of Ketamine
NMDA receptor antagonist
Inhibits reuptake of serotonin and catecholamines
Potent short acting sedative
Pharmacokinetics of Ketamine
Absorption; Highly lipid soluble so rapid onset
Distribution; Effect is terminated by redistribution to inactive tissue sites. Low protein binding
Metabolism; Metabolised in the liver via the P450 enzymes to inactive metabolites
Elimination; metabolites are excreted in the urine
System effects of Ketamine
CNS; dissociative anaesthesia, profound analgesia, Cerebral vasodilation. Potential anticonvulsant properties
CVS; haemodynamically stable, increase HR, BP, CO and myocardial oxygen consumption
Respiratory; Maintains airway reflexes, minimal respiratory depression, bronchodilator effects. Can cause lacrimation and laryngospasm in children
Ocular; nystagmus
Adverse effects of ketamine
CNS - emergence phenomenon, dysphoria, hallucinations
GI - nausea, vomiting
Respiratory - latyngospasm, increased salivation
Pharmacokinetics of Thiopentone
Administration; IV bolus
Rapidly crosses BBB, highly lipid soluble, redistributes to muscle and fat
metabolised in the liver
excreted by the kidney
Advantages of Thiopentone
rapid onset
amnesic
reduction in ICP
anitconvulsant
Adverse effects of thiopentone
hypotension
reduced stroke volume and cardiac output
apnoea
Mechanism of Action of Suxamethonium
Deploarizing neuromuscular blocker
2 acetylcholine molecules linked end to end
2 phases;
1. depolarising
- reacts with nicotinic receptor to open channel
- depolarises the motor endplate which spread to adjacent membranes
- causes fasiculations
2. desensitising
- continued repeat exposure to sux
end plate depolarisation increases
membrane repolarizes but cannot depolarise
unresponsive to subsequent impulses
causes a flaccid paralysis
Pharmacokinetics of suxamethonium
Administration; IV
Distribution; rapid onset 30-60 seconds, short duration 2-8 minutes
Metabolism - Hydrolysed rapidly by plasma pseudocholinesterase
Adverse effects of suxamethonium
Muscle pain and fasiculations
Bradycardia
release of potassium - especially in burns and trauma
raised IOP and raised ICP
risk of malignant hyperthermia
risk of prolonged paralysis in cases of reduced or abnormal cholinesterase
Mechanism of action of Rocuronium
A non deploarizing neuromuscular blocker
a competitive inhibitor of acetylcholine at the nicotinic receptors
In large doses it can enter the pore of the ion channel and cause a stronger block
Pharmacokinetics of Rocuronium
Administered; IV bolus 1.2mg/kg onset 40/60 seconds
Distribution ; Rapid, highly ionized, small Vd. Duration of 20-75 minutes
metabolised in the liver, short half life
Eliminated the urine
How does suxemethonium differ from rocuronium?
Duration of suxamethonium is shorter - 5-10 mins
Suzamethonium is depolarising NMB
Rocuronium is non depolarising
Suxamethonium metabolised in the plasma
Rocuronium in the liver
Pharmacodynamics of ethanol
CNS; sedation, disinhibition, impaired judgement, impaired motor skills, ataxia, slurred speech, coma, respiratory depression
CVS; decreased contractility
Smooth muscle vasodilation = hypothermia
Pharmacokinetics of ethanol
Absorption; rapidly absorbed from the GIT (water soluble)
Distribution; Rapid, Vd is total body water
Metabolism; mostly in the liver by alcohol dehydrogenase via zero order kinetics
Excretion; lung and urine
What is zero order kinetics
Elimination occurs at a constant rate independent of drug concentration
What drugs have zero order kinetics
phenytoin, theophylline, warfarin, salicylate, heparin, ethanol
Mechanism of action of benzodiazepines
Binds to components of the GABA-A receptor in neuronal membranes in the CNS
This receptor is a chloride channel
Enhance GABAs effects without directly activating the channel
causes an increased frequency of channel opening
Organ effects of Diazepam
Sedation - calming effect, anxiolysis
Hypnosis and anaesthesia at higher doses
anticonvulsant effect
muscle relaxation
respiratory and cardiovascular depression
Mechanism of action of carbamazepine
Sodium channel blockers
Binds to those in an inactive state and stabilises them there
Inhibits high frequency repetitive firing neurones
Pharmacokinetics of carbamazepine
100% oral bioavailability
Peak level 6-8 hours
70% protein bound
low clearance, 36 hours half life
induces its own metabolism via _450 system effect so dose increase required in the first few weeks of treatment
Adverse effects of of carbamazepine?
ataxia
diplopia
sedation
blood dyscrasias - aplastic anaemia, agranulocytosis
skin rash
drug interactions with p450 metabolised drugs
Pharmacokinetics of phenytoin
Administration; Oral, IV
high oral bioavailabiliity
Peak serum concentration 3-12 hours
Highly plasma protein bound with moderate volume of distribution
Metabolised in the liver to an inactive metabolites and then renal excretion
Elimination is dose dependent
lower dose is first order kinetics but at higher doses enzymes become saturated and shifts to zero order kinetics
Half life is variable
What is the mechanism of action of Phenytoin
Sodium channel blockade
Prolongation of the inactive state of the Na channel
enhances GABA release
Work to inhibit the generation of rapidly repetitive action potentials
Why use a loading dose of phenytoin
Need 4 half lives to reach a steady state, so to reach target concentration rapidly
Risks of IV phenytoin
Hypotension and bradycardia with rapid infusion
local necrosis if there is extravasation
Purple glove syndrome - black discolouration distal to the IV site
Adverse effects of phenytoin
Nystagmus and loss of smooth pursuits is normal with therapeutic levels and not concerning
Anyone with ataxia and diplopia need a decrease in their dose
Ginigival hyperplasia and hirsutism can occue over long term use
Osteolmalacia, abnormal rashes, low vitamin D
Foetal abnormalities
Sedation, coma, cerebellar toxicity
Mechanism of action of levetiracetam
Binds the SV2 synaptic vessel protein
Undergoes endocytosis and binds in the vesicle
Prevents release of glutamine during increased frequency activity
Pharmacokinetics of levetiracetam
Given orally or IV , rapid oral absorption just over 1 hour
Low protein binding
Half life 6-8 hours so BD dosing
2/3 excreted in urine
1/3 deaminated in the blood
No liver metabolism = mineral interactions compared to other antiepileptics
Side effects of levetiracetam
Mild; drowsiness, ataxia, dizziness
severe; behavioural or mood changes - aggression/anxiety
What is the dose of levetiracetam in status epilepticus
Paeds 40mg/kg IV/IO up to 3g
Adults 60mg/kg IV/IO up to 4.5g
Mechanism of action of sodium valproate
Unknown
What are the adverse effects of Sodium Valproate
Mild; nausea, vomiting, abdominal pain
Severe; Cerebral oedema and coma
Hepatic toxicity including acute liver failure
Thrombocytopaenia and bruising from bone marrow depression
Neural tube defects if used in pregnancy
Hyperammonaemia leading to sedation
Inhibits metabolism of p450 enzyme system
Directly displaces phenytoin from plasma proteins
Increases level of carbomazapine
Decreases the clearance of lamotrigine
Mechanism by which serotonin syndrome occurs
Excessive stimulation of serotonin receptors in the CNS due to overdose of a single drug or concurrent use of several drugs
Predictable rather than idiosyncratic
How do drugs cause excessive stimulation of serotonin receptors
Inhibition of serotonin metabolism - amphetamines
Prevention of serotonin reuptake in nerve terminals - fluoxetine, sertraline, venlafaxine, tramadol, TCAs
serotonin release or increased intake of serotonin precursors - tryrophan, lithium
Mechanism of action of tricyclic antidepressants?
Inhibition of serotonin and noradrenaline reuptake
Increases the amount of serotonin and noradrenaline in certain parts of the brain and spinal cord
Also block sodium channels, potassium channels, M1 receptors, Histamine 1 receptors, post synaptic alpha 1 adrenergic receptors
Pharmacokinetics of tricyclics antidepressants
Well absorbed orally
Bioavailability 40-50%
long half life
high first pass metabolism
high protein binding
high lipid solubility
large volume distribution
metabolism in the liver with active metabolites
Effects of overdose in TCAs
Cardiac; tachycardia, hypotension, prolonged PR, wide QRS, long QT, VT , VF
CNS; Drowsiness, delerium, seziures, coma
Anticholinergic effects; agitation, mydriasis, warm dry flushed skin, urinary retention, ileus
Pharmacokinetics of lithium
Administration; orally, rapid and near complete absorption, peak concentration at 1-2 hours but complete 6-8 hours
Volume distribution is in total body water - very slow distribution from extra to intracellular compartments
No protein binding
No metabolism
Excreted unchanged in urine 20% of the creatinine clearance
Plasma half life is 20 hours
Some drug interactions with lithium
Thiazide diuretics - cause reduction in lithium clearance
Newer NSAIDS reduce clearance
Osmotic or loop diuretics actually increase clearance
Why is levodopa used in combination of carbidopa
Carbidopa is a peripheral dopa carboxylase inhibitor.
It doesn’t cross the BBB, reduces the peripheral metabolism of levodopa which leads to increased half life and more dopa being available to enter the CNS to exert its effects
What are the adverse effects of levodopa ?
GIT; anorexia, nausea, vomiting is common due to stimulation of emetic centre in the brain
CVS; arrhythmias
Dyskinesis
Behavioural changes
Gout, abnormal LFTs
How do sumatriptans work in treatment in migraines?
Triptans are selective agonists for 5HT-1 receptors found on these vessels
Cause vasoconstriction, preventing symptoms
Pharmacokinetics of Triptans?
Bioavailability is a low/varied 10-70%
So given subcut or intranasal more often than orally
Half life is 2-3 hours
Pros and cons to sumatriptan use?
Pros; only usually mild side effects, tingling weakness
Cons; contraindicated in patients with IHD, expensive
Pharmacodynamics of adenosine
Slow conduction through the Av node
Blocks specific adenosine receptors
Mechanism is increased K+ conductance and decreased cAMP induced calcium influx
ECG = increased PR interval
Pharmacokinetics of adenosine
Administration: IV with rapid absorption
Distribution to most cells
Metabolism : rapidly degraded by cells, deaminated and phosphorylated
Half life is 10 seconds
Indication of Adenosine
SVT
Diagnostic tachyarrhythmias
Adjunct to thallium scanning
Pharmacodynamics of adrenaline
Binds to alpha and beta receptors
Act through G proteins
Beta stimulates cAMP
Alpha leads to inhibition cAMP
- relaxes smooth muscle of bronchi
- cardiac stimulation
- skeletal muscular vascular dilation
Structure/class amiloride
Potassium sparing diuretic
Not an aldosterone antagonist
Pharmacodynamics of amiloride
Reduces Na+ absorption in collecting tubules and ducts and inhibits tubular secretion of K+
Pharmacokinetics of amiloride
Administration: orally 5-20mg daily dose
Absorption: excreted unchanged by kidneys
Peak plasma levels in 3-4 hours
Half life 6-9 hours
Indication of amiloride
Used to spare potassium when other diuretics are the main agents
Congestive heart failure and HTN
Hepatic cirrhosis with ascites
Indication of aminophylline
Bronchospasm
Pharmacodynamics of aminophylline
Bronchodilator in reversible airways obstruction
Also causes diuresis, cns and cardiac stimulation and gastric acid secretion by blocking phosphodiesterase.
Increases tissue concentrations of cAMP which promotes catecholamines stimulation of lipolysis, glycogenolysis and gluconeogenesis
Induces release of adrenaline from adrenal medulla